The Pharmacy Times® Dermatology resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
What can we help you find?
If approved for this indication, dupilumab (Dupixent) will be the first systemic biologic medicine to treat adolescents with moderate-to-severe atopic dermatitis.
Sun Pharma announced the availability of its treatment for moderate-to-severe plaque psoriasis in the United States.
Tildrakizumab-asmn (Ilumya) is indicated for the treatment of moderate-to-severe plaque psoriasis in adults.
Tildrakizumab-asmn (Ilumya), an injectable interleukin-23 (IL-23) inhibitor, was approved by the FDA in March for adults who are candidates for systemic therapy or phototherapy.
Top news of the day from across the health care landscape.
Phase 3 trial results for dupilumab (Dupixent) demonstrate improvement in skin clearing, itch, and certain quality of life measurements for adolescents with atopic dermatitis.
In its latest report, the Institute for Clinical and Economic Review (ICER) evaluated the efficacy and value of newer targeted agents that treat moderate-to-severe plaque psoriasis compared with non-targeted therapies.
Patients whose psoriasis covers a large percentage of their body face a significantly higher risk of death than those who do not have the disease, according to results of a recent study.
The FDA has approved an updated label for Eli Lilly’s ixekizumab (Taltz) injection 80 mg/mL to include data in psoriasis involving the genital area.
Risankizumab shows promise as an important treatment option for people living with plaque psoriasis.
The FDA has approved ILUMYA (tildrakizumab-asmn, Sun Pharma) for treating adults with moderate-to-severe plaque psoriasis.